Redmile Group LLC trimmed its stake in LivaNova PLC (NASDAQ:LIVN – Free Report) by 8.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 108,354 shares of the company’s stock after selling 9,700 shares during the period. LivaNova makes up about 0.5% of Redmile Group LLC’s investment portfolio, making the stock its 26th biggest position. Redmile Group LLC’s holdings in LivaNova were worth $6,887,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. UMB Bank n.a. increased its position in shares of LivaNova by 22.6% during the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after acquiring an additional 179 shares during the period. State of Michigan Retirement System raised its stake in shares of LivaNova by 1.5% during the first quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock valued at $833,000 after acquiring an additional 200 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the period. Parallel Advisors LLC boosted its holdings in shares of LivaNova by 28.8% in the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after purchasing an additional 283 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its stake in LivaNova by 2.7% in the first quarter. Oregon Public Employees Retirement Fund now owns 11,250 shares of the company’s stock worth $715,000 after purchasing an additional 300 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
LIVN has been the topic of several research reports. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Freedom Capital upgraded LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Robert W. Baird dropped their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $81.38.
LivaNova Stock Up 1.9%
LivaNova stock opened at $82.09 on Wednesday. The business has a fifty day moving average of $78.66 and a two-hundred day moving average of $69.83. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The firm has a market cap of $4.51 billion, a P/E ratio of 42.10 and a beta of 0.86. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $85.27.
LivaNova (NASDAQ:LIVN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period last year, the business posted $0.88 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts forecast that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.
Insider Buying and Selling at LivaNova
In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is owned by company insiders.
About LivaNova
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Read More
- Five stocks we like better than LivaNova
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN – Free Report).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
